KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities: 2017-2025

Historic Other Non-Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 6 years, with Sep 2025 value amounting to $32.6 million.

  • Amneal Pharmaceuticals' Other Non-Current Liabilities rose 24.59% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year increase of 24.59%. This contributed to the annual value of $50.9 million for FY2024, which is 71.50% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Other Non-Current Liabilities of $32.6 million as of Q3 2025, which was up 26.39% from $25.8 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $87.5 million during Q4 2022, with a 5-year trough of $23.2 million in Q1 2025.
  • For the 3-year period, Amneal Pharmaceuticals' Other Non-Current Liabilities averaged around $32.8 million, with its median value being $29.7 million (2023).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 124.84% in 2022, then crashed by 66.07% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $38.9 million in 2021, then skyrocketed by 124.84% to $87.5 million in 2022, then crashed by 66.07% to $29.7 million in 2023, then spiked by 71.50% to $50.9 million in 2024, then increased by 24.59% to $32.6 million in 2025.
  • Its Other Non-Current Liabilities was $32.6 million in Q3 2025, compared to $25.8 million in Q2 2025 and $23.2 million in Q1 2025.